Latest & greatest articles for montelukast

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on montelukast or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on montelukast and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for montelukast

1. Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions

Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Montelukast (...) (Singulair): reminder of the risk of neuropsychiatric reactions Prescribers should be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the benefits and risks of continuing treatment if they occur. Published 19 September 2019 From: Therapeutic area: , , Contents Advice for healthcare professionals: be alert for neuropsychiatric reactions in patients taking montelukast; events have been reported in adults, adolescents, and children (see list of reported events

2019 MHRA Drug Safety Update

2. Systematic review of montelukast's efficacy and safety for the treatment of infantile bronchiolitis

Systematic review of montelukast's efficacy and safety for the treatment of infantile bronchiolitis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

3. Montelukast for the treatment of allergic rhinitis: a systematic review and meta-analysis

Montelukast for the treatment of allergic rhinitis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

4. Efficacy of montelukast for the treatment of pediatric allergic purpura (PAP): a systematic review of randomized controlled trials

Efficacy of montelukast for the treatment of pediatric allergic purpura (PAP): a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

5. Efficacy and safety of fluticasone/salmeterol (Seretide) compared to montelukast (Singulair) in bronchial asthma in under-aged population: a systematic review and meta-analysis

Efficacy and safety of fluticasone/salmeterol (Seretide) compared to montelukast (Singulair) in bronchial asthma in under-aged population: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

6. Montelukast

Montelukast Top results for montelukast - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for montelukast The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

7. Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial (PubMed)

Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial Otitis media is one of the most common infections among children and is a complication in about 30% of common colds. The most common complication of acute otitis media is otitis media with effusion. Some studies have reported the effects of montelukast and mometasone nasal spray in treatment of otitis media with effusion. However, current information is inadequate (...) in this issue.To compare the effectiveness of montelukast and mometasone nasal spray in treatment of otitis media with effusion in children attending Koodakan hospital in Bandar Abbas, Iran.This randomized controlled trial was done on 2- to 6-year-old children attending Koodakan Hospital in Bandar Abbas, southern Iran, in 2014. Patients were divided into three groups of montelukast, mometasone, and control group. Audiometry was done for all patients at baseline and four weeks after treatment. Patients were

Full Text available with Trip Pro

2017 Electronic physician Controlled trial quality: uncertain

8. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma (PubMed)

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed. We hypothesized that this drug might provide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients (...) whose symptoms are uncontrolled by inhaled corticosteroids and long-acting β-agonists.We sought to examine the efficacy, safety, and mode of action of the addition of roflumilast and montelukast versus montelukast alone in patients with moderate-to-severe asthma.In a phase 2, randomized, double-blind, placebo-controlled, multiple-dose, 2-sequence, crossover study, 64 patients were randomized to receive 500 μg of roflumilast plus montelukast followed by placebo plus 10 mg of montelukast (sequence AB

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: predicted high

9. Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial

Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate-5-lipoxygenase (ALOX5) promoter genotype. Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested

Full Text available with Trip Pro

2015 NIHR HTA programme

10. Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines

Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation CADTH. Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014 Authors' conclusions One study found that montelukast improved respiratory disturbances in children with mild to moderate obstructive sleep apnea (OSA). No published trials regarding the use of montelukast in adults with OSA were identified

2014 Health Technology Assessment (HTA) Database.

11. Montelukast

Montelukast USE OF MONTELUKAST IN PREGNANCY 0344 892 0909 USE OF MONTELUKAST IN PREGNANCY (Date of issue: August 2015 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Montelukast is a cysteinyl leukotriene type-1 receptor (...) antagonist licensed as an anti-asthmatic medication for patients inadequately controlled by inhaled corticosteroids or short-acting beta-agonists, and for asthmatics with exercise-induced bronchoconstriction. Although the available data are limited both by lack of power and/or formal statistical analysis in some studies, there is currently no good evidence that montelukast exposure during pregnancy increases the overall risk of congenital malformation, spontaneous abortion, intrauterine death, decreased

2014 UK Teratology Information Service

12. Randomised controlled trial: Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term

Randomised controlled trial: Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term Article Text Therapeutics Randomised

2013 Evidence-Based Medicine (Requires free registration)

13. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial (PubMed)

Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial Although leukotriene receptor antagonists have an established role in the management of patients with chronic asthma, their efficacy in an acute asthma exacerbation is not fully known.87 adults with acute asthma requiring hospitalisation were randomly assigned to receive either montelukast 10 mg or placebo on admission and every evening thereafter for 4 weeks (when they were reviewed (...) as outpatients). All patients were admitted under the care of a consultant chest physician and received full care for acute asthma according to the British Thoracic Society guidelines. The primary end point was the difference in peak expiratory flow (PEF) between active and placebo treatment the morning following admission.Primary end point data were analysed for 73 patients. At study entry, patients who received montelukast (n=37) had a mean (±SD) PEF of 227.6 (±56.9) l/min (47.6% predicted) and those who

Full Text available with Trip Pro

2011 EvidenceUpdates Controlled trial quality: predicted high

14. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial (PubMed)

Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial To study the effect of the addition of a single dose of oral montelukast to standard therapy in acute moderate to severe asthma.Double-blind randomised controlled trial. Setting Emergency room/outpatient paediatric services of a tertiary care hospital.Children aged 5-15 years (without prior (...) use of montelukast) with acute moderate to severe asthma exacerbation, as defined using Modified Pulmonary Index Score (MPIS) > or =9, were enrolled.Children received montelukast (5-12 years: 5 mg and >12 years: 10 mg) or placebo orally in addition to the standard therapy. MPIS and forced expiratory volume in 1 second (FEV(1)) were recorded before administering study medication and thereafter, hourly for 4 hours.The primary outcome was decrease in MPIS to less than 9 at the end of 4 hours.117

Full Text available with Trip Pro

2010 EvidenceUpdates Controlled trial quality: predicted high

15. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis (PubMed)

The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis To compare the efficacy of inhaled corticosteroids (ICS) versus montelukast (MONT) in schoolchildren and adolescents with mild-moderate persistent asthma.Randomised, prospective, controlled trials published January 1996 to November 2009 with a minimum of 4 weeks of ICS versus MONT and of ICS versus MONT+ICS were retrieved through Medline, Embase

2010 EvidenceUpdates

16. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial (PubMed)

Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial To examine whether outpatient post-stabilization therapy with montelukast produces more treatment failures than prednisolone.In this randomized, double-blind, double-dummy non-inferiority trial, 130 children 2 to 17 years of age with mild to moderate acute asthma stabilized with prednisolone in the emergency department received 5 daily treatments with either prednisolone (...) or montelukast after discharge. The primary outcome was treatment failure within 8 days (ie, an asthma-related unscheduled visit, hospitalization, or additional systemic corticosteroids).The rates of treatment failure were 7.9% in the prednisolone group and 22.4% in the montelukast group (95% CI, 26.5%-2.4%). Treatment was more likely to fail in younger patients (odds ratio, 4.9). In the montelukast group, more patients received additional pharmacotherapy than in patients receiving prednisolone (23.9% versus

2010 EvidenceUpdates Controlled trial quality: predicted high

17. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis

The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis Castro-Rodriguez JA, Rodrigo GJ CRD summary This review concluded (...) that inhaled corticosteroids led to less asthma exacerbations compared with montelukast for the prevention of asthma exacerbations in children with mild-to-moderate persistent asthma. Although there was uncertainty related to some aspects of the reporting of the review, the authors’ conclusions reflected the evidence presented and appear to be broadly reliable. Authors' objectives To assess the efficacy of inhaled corticosteroids and montelukast for the prevention of asthma exacerbations in children

2010 DARE.

18. Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis

Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Saverno KR, Seal B, Goodman MJ, Meyer K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of several second-generation antihistamines (levocetirizine, desloratadine, and fexofenadine) and montelukast for uncomplicated allergic rhinitis, focusing on improvements in quality

2009 NHS Economic Evaluation Database.

19. Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best?

Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Miceli Sopo S, Onesimo R, Radzik D, Scala G, Cardinale F CRD summary The review’s conclusion appeared to be that inhaled corticosteroids were effective and should be the first choice (...) treatment for paediatric persistent asthma, with montelukast as a possible alternative in children unable to use inhaled corticosteroids. The reliability of these conclusions is unclear given numerous limitations in the conduct and reporting of the review. Authors' objectives To compare the effectiveness of montelukast compared with inhaled corticosteroids as monotherapy in the prevention of asthma in children. Searching MEDLINE was searched (up to December 2008) for English-language papers. Search

2009 DARE.

20. Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma

Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma Article Text

2008 Evidence-Based Medicine (Requires free registration)